STAAR Surgical Reports Second Quarter 2017 Results
MONROVIA, Calif., Aug. 2, 2017 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye today reported financial results for the second quarter ended June 30, 2017.
Second Quarter 2017 Overview
- Quarterly Net Sales of $21.9 Million Up 5% from the Prior Year Quarter
- ICL Sales Up 6% and Units Up 11% from the Prior Year Quarter
- IOL Sales Down 14% and Units Down 7% from the Prior Year Quarter
- Gross Margin Improved to 70.5% of Sales from 69.7% of Sales in the Prior Year Quarter
- Quarterly Net Loss of $0.02 per Share; Adjusted Net Loss of $0.01 per Share
- Cash, Cash Equivalents and Restricted Cash Ended the Quarter at $13.6 Million
- Awarded CE Mark Approval for the EVO+ Visian ICL with Aspheric (EDOF) Optic
- Currently CE Marked and Commercially Available Products Re-Certified for 5 Years
"Our work to advance the ICL to its rightful position as a premium and primary refractive vision correction solution continues to spur strong growth in many countries globally. Unit growth in Q1 of 20% followed by unit growth of 11% in Q2 in spite of anticipated challenges in the India and Korea markets for the quarter are an indicator of continued strong progress. During Q2, the Toric ICL achieved another new quarterly record for shipments. ICL unit highlights for Q2 include growth in Canada of 119%, China of 57%, and Japan of 24%. Region growth was strong in ICL units as well with North America and Asia Pacific Regions recording 15% unit growth respectively. With the positioning of the sale of the ICL for the more competitive lower diopter range lenses and the addition of strategic accounts with incentivized volume commitments; our average selling prices have been appropriately adjusted to gain share in targeted markets. Our position as market leader and superior refractive surgical solution for high Myopes, however, continues to earn premium pricing," said Caren Mason, President and CEO.
"Our first-in-man clinical trial for the next generation ICL with EDOF continued during the quarter and the results continue to be positive. In July, DEKRA, our European Union notified regulatory body, re-certified our facilities as compliant with ISO 13485 and re-certified the CE marking for all of our currently certified and commercially available medical devices. With regard to FDA remediation, we completed our internal work in the first quarter of 2017 and have notified the FDA that we are ready for inspection," added Ms. Mason.
Financial Overview
Net sales were $21.9 million for the second quarter of 2017, up 5% compared to $21.0 million reported in the prior year quarter. The sales increase was driven by ICL revenue and unit growth of 6% and 11%, respectively, and strong injector part sales. Sales of IOLs decreased 14% compared to the prior year quarter.
For the second quarter of 2017, gross profit margin was 70.5% compared to the prior year period of 69.7%. The increase in gross margin for the quarter is due to a 12% increase in Toric ICL sales (our highest margin product), a reduction in inventory reserves and improved unit costs, partially offset by lower average selling prices and unfavorable product mix due to increased sales of low margin injector parts. Inventory provisions in 2016 were unfavorably impacted by the discontinuance of silicone IOL sales in the U.S. and V4b ICL sales internationally.
Operating expenses for the quarter were flat at $16.8 million compared to the prior year quarter. General and administrative expense was $4.8 million, 3.4% lower than the prior year quarter. Marketing and selling expense was $7.3 million, up 1.9% compared to the prior year quarter. Research and development expense was $4.7 million, up 1.1% compared to the prior year quarter.
The net loss for the second quarter of 2017 was $1.0 million or approximately $0.02 per share compared with a net loss of $2.1 million or $0.05 per share for the prior year quarter.
The Adjusted Net Loss for the second quarter of 2017 was $0.4 million or $0.01 Adjusted Net Loss Per Share, compared with an Adjusted Net Loss of $1.0 million or $0.02 Adjusted Net Loss Per Share for the prior year quarter. The reconciliation between GAAP and non-GAAP financial information is provided in the financial tables included with this release.
Cash, cash equivalents and restricted cash at June 30, 2017 totaled $13.6 million, compared to $14.1 million at the end of the fourth quarter of 2016 and $12.8 million at the end of the second quarter of 2016. Continued focus on optimizing the Company's cash position through revenue growth, expense mitigation, and working capital management enabled the Company to maintain a cash balance consistent with the $13.6 million reported for the end of the first quarter of 2017.
Conference Call
The Company will host a conference call and webcast on Wednesday, August 2, 2017 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 54127075), please dial 855-765-5684 for domestic participants and 262-912-6252 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.
A taped replay of the conference call (Conference ID 54127075) will be available beginning approximately one hour after the call's conclusion for seven days. This replay can be accessed by dialing 855-859-2056 for domestic callers and 404-537-3406 for international callers. An archived webcast will also be available at www.staar.com.
Use of Non-GAAP Financial Measures
This press release includes supplemental non-GAAP financial information, which STAAR believes investors will find helpful in understanding its operating performance. "Adjusted Net Loss" and "Adjusted Net Loss Per Share" exclude the following items that are included in "Net Loss" as calculated in accordance with U.S. generally accepted accounting principles ("GAAP"): gain or loss on foreign currency transactions, stock-based compensation expenses, and quality remediation expenses. Management believes that "Adjusted Net Loss" and "Adjusted Net Loss Per Share" are useful to investors in gauging the outcome of the key drivers of the business performance: the ability to increase sales revenue and our ability to increase profit margin by improving the mix of high value products while reducing the costs over which management has control. Management has excluded quality remediation expenses because their inclusion may mask underlying trends in our business performance.
Management has also excluded gains and losses on foreign currency transactions because of the significant fluctuations that can result from period to period as a result of market driven factors. Stock-based compensation expenses consist of expenses for stock options and restricted stock under the Financial Accounting Standards Board's Accounting Standards Codification (ASC) 718. In calculating Adjusted Net Loss and Adjusted Net Loss Per Share, STAAR excludes these expenses because they are non-cash expenses and because of the complexity and considerable judgment involved in calculating their values. In addition, these expenses tend to be driven by fluctuations in the price of our stock and not by the same factors that generally affect our other business expenses.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or "ICL". More than 700,000 Visian ICLs have been implanted to date. To learn more about the ICL go to: www.discovericl.com. STAAR has approximately 340 full-time equivalent employees and markets lenses in over 60 countries. Headquartered in Monrovia, CA, the company operates manufacturing facilities in Aliso Viejo, CA and Monrovia, CA. For more information, please visit the Company's website at www.staar.com.
Safe Harbor
All statements in this press release that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, including those relating to the plans, strategies, and objectives of management for future operations or prospects for achieving such plans, expectations for sales, marketing and clinical initiatives, completion of remediation or other expense, success and timing of new or improved products, clinical trials, research and development activities, investment imperatives, and any statements of assumptions underlying any of the foregoing. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the Company's Annual Report on Form 10-K for the year ended December 30, 2016 under the caption "Risk Factors," which is on file with the Securities and Exchange Commission and available in the "Investor Information" section of the company's website under the heading "SEC Filings." We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events.
These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: our limited capital resources and limited access to financing; global economic conditions; changes in currency exchange rates; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before approval (including but not limited to FDA requirements regarding the Visian Toric ICL and/or actions related to the FDA Warning Letter and Form FDA-483s), or to take enforcement action; research and development efforts; the purchasing patterns of our distributors carrying inventory in the market; and the willingness of surgeons and patients to adopt a new or improved product and procedure. The Visian Toric ICL and the Visian ICL with CentraFLOW, now known as EVO Visian ICL, are not yet approved for sale in the United States.
| CONTACT: |
Investors & Media |
| EVC Group |
|
| Brian Moore, 310-579-6199 |
|
| Doug Sherk, 415-652-9100 |
| STAAR Surgical Company |
||||
| Consolidated Balance Sheets |
||||
| (in 000's) |
||||
| Unaudited |
||||
| June 30, |
December 30, |
|||
| ASSETS |
2017 |
2016 |
||
| Current assets: |
||||
| Cash and cash equivalents |
$ 13,438 |
$ 13,999 |
||
| Accounts receivable trade, net |
16,426 |
16,344 |
||
| Inventories, net |
13,458 |
14,825 |
||
| Prepayments, deposits, and other current assets |
4,474 |
4,349 |
||
| Total current assets |
47,796 |
49,517 |
||
| Property, plant, and equipment, net |
11,619 |
11,790 |
||
| Intangible assets, net |
383 |
473 |
||
| Goodwill |
1,786 |
1,786 |
||
| Deferred income taxes |
1,104 |
1,105 |
||
| Other assets |
948 |
772 |
||
| Total assets |
$ 63,636 |
$ 65,443 |
||
| LIABILITIES AND STOCKHOLDERS' EQUITY |
||||
| Current liabilities: |
||||
| Line of credit |
$ 4,460 |
$ 4,283 |
||
| Accounts payable |
6,917 |
8,311 |
||
| Obligations under capital leases |
1,252 |
1,198 |
||
| Other current liabilities |
6,353 |
7,275 |
||
| Total current liabilities |
18,982 |
21,067 |
||
| Obligations under capital leases |
1,128 |
1,339 |
||
| Deferred income taxes |
889 |
881 |
||
| Asset retirement obligations |
203 |
195 |
||
| Deferred rent |
61 |
59 |
||
| Pension liability |
4,080 |
3,997 |
||
| Total liabilities |
25,343 |
27,538 |
||
| Stockholders' equity: |
||||
| Common stock |
411 |
407 |
||
| Additional paid-in capital |
200,921 |
197,657 |
||
| Accumulated other comprehensive loss |
(756) |
(1,050) |
||
| Accumulated deficit |
(162,283) |
(159,109) |
||
| Total stockholders' equity |
38,293 |
37,905 |
||
| Total liabilities and stockholders' equity |
$ 63,636 |
$ 65,443 |
| STAAR Surgical Company |
||||||||||||||||||||
| Consolidated Statements of Operations |
||||||||||||||||||||
| (In 000's except for per share data) |
||||||||||||||||||||
| Unaudited |
||||||||||||||||||||
| Three Months Ended |
Six Months Ended |
|||||||||||||||||||
| % of |
June 30, |
% of |
July 1, |
Fav (Unfav) |
% of |
June 30, |
% of |
July 1, |
Fav (Unfav) |
|||||||||||
| Sales |
2017 |
Sales |
2016 |
Amount |
% |
Sales |
2017 |
Sales |
2016 |
Amount |
% |
|||||||||
| Net sales |
100.0% |
$21,936 |
100.0% |
$20,974 |
$ 962 |
4.6% |
100.0% |
$42,286 |
100.0% |
$ 40,243 |
$ 2,043 |
5.1% |
||||||||
| Cost of sales |
29.5% |
6,462 |
30.3% |
6,348 |
(114) |
-1.8% |
28.9% |
12,235 |
31.4% |
12,624 |
389 |
3.1% |
||||||||
| Gross profit |
70.5% |
15,474 |
69.7% |
14,626 |
848 |
5.8% |
71.1% |
30,051 |
68.6% |
27,619 |
2,432 |
8.8% |
||||||||
| Selling, general and administrative expenses: |
||||||||||||||||||||
| General and administrative |
21.7% |
4,761 |
23.5% |
4,928 |
167 |
3.4% |
23.9% |
10,120 |
33.3% |
13,393 |
3,273 |
24.4% |
||||||||
| Marketing and selling |
33.4% |
7,321 |
34.2% |
7,181 |
(140) |
-1.9% |
32.8% |
13,851 |
36.9% |
14,856 |
1,005 |
6.8% |
||||||||
| Research and development |
21.5% |
4,712 |
22.2% |
4,659 |
(53) |
-1.1% |
22.5% |
9,495 |
28.7% |
11,565 |
2,070 |
17.9% |
||||||||
| Total selling, general, and administrative expenses |
76.6% |
16,794 |
79.9% |
16,768 |
(26) |
-0.2% |
79.2% |
33,466 |
98.9% |
39,814 |
6,348 |
15.9% |
||||||||
| Operating loss |
-6.1% |
(1,320) |
-10.2% |
(2,142) |
822 |
38.4% |
-8.1% |
(3,415) |
-30.3% |
(12,195) |
8,780 |
72.0% |
||||||||
| Other income (expense): |
||||||||||||||||||||
| Interest expense, net |
-0.1% |
(32) |
-0.1% |
(29) |
(3) |
-10.3% |
-0.1% |
(61) |
-0.1% |
(57) |
(4) |
-7.0% |
||||||||
| Gain (loss) on foreign currency transactions |
1.7% |
380 |
-2.0% |
(416) |
796 |
— |
0.7% |
294 |
0.1% |
42 |
252 |
— |
||||||||
| Royalty income |
0.6% |
128 |
1.7% |
351 |
(223) |
-63.5% |
0.6% |
259 |
0.9% |
373 |
(114) |
-30.6% |
||||||||
| Other income (expense), net |
0.1% |
19 |
-0.2% |
(38) |
57 |
— |
0.1% |
36 |
-0.2% |
(82) |
118 |
— |
||||||||
| Total other income (expense), net |
2.3% |
495 |
-0.6% |
(132) |
627 |
— |
1.3% |
528 |
0.7% |
276 |
252 |
91.3% |
||||||||
| Loss before provision (benefit) for income taxes |
-3.8% |
(825) |
-10.8% |
(2,274) |
1,449 |
63.7% |
-6.8% |
(2,887) |
-29.6% |
(11,919) |
9,032 |
75.8% |
||||||||
| Provision (benefit) for income taxes |
0.7% |
146 |
-0.6% |
(131) |
(277) |
— |
0.7% |
287 |
-4.3% |
(1,735) |
2,022 |
— |
||||||||
| Net loss |
-4.5% |
$ (971) |
-10.2% |
$ (2,143) |
$ 1,172 |
54.7% |
-7.5% |
$ (3,174) |
-25.3% |
$(10,184) |
$ 7,010 |
68.8% |
||||||||
| Net loss per share - basic and diluted |
$ (0.02) |
$ (0.05) |
$ (0.08) |
$ (0.25) |
||||||||||||||||
| Weighted average shares outstanding - basic and diluted |
40,933 |
40,210 |
40,841 |
40,097 |
||||||||||||||||
| STAAR Surgical Company |
|||||||||
| Consolidated Statements of Cash Flows |
|||||||||
| (in 000's) |
|||||||||
| Unaudited |
|||||||||
| Three Months Ended |
Six Months Ended |
||||||||
| June 30, |
July 1, |
June 30, |
July 1, |
||||||
| 2017 |
2016 |
2017 |
2016 |
||||||
| Cash flows from operating activities: |
|||||||||
| Net loss |
$ (971) |
$ (2,143) |
$ (3,174) |
$ (10,184) |
|||||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |
|||||||||
| Depreciation of property and equipment |
792 |
646 |
1,548 |
1,237 |
|||||
| Amortization of long-lived intangibles |
56 |
57 |
110 |
111 |
|||||
| Deferred income taxes |
16 |
(163) |
9 |
(1,802) |
|||||
| Change in net pension liability |
(36) |
102 |
30 |
220 |
|||||
| Stock-based compensation expense |
868 |
300 |
1,378 |
7,758 |
|||||
| Loss on disposal of property and equipment |
5 |
17 |
72 |
17 |
|||||
| Provision for sales returns and bad debts |
(166) |
111 |
66 |
89 |
|||||
| Inventory provision |
488 |
900 |
789 |
1,182 |
|||||
| Changes in working capital: |
|||||||||
| Accounts receivable |
(645) |
252 |
(21) |
(65) |
|||||
| Inventories |
807 |
149 |
908 |
431 |
|||||
| Prepayments, deposits and other current assets |
805 |
494 |
(278) |
(418) |
|||||
| Accounts payable |
(610) |
1,715 |
(1,767) |
1,280 |
|||||
| Other current liabilities |
(2,075) |
74 |
(961) |
(324) |
|||||
| Net cash provided by (used in) operating activities |
(666) |
2,511 |
(1,291) |
(468) |
|||||
| Cash flows from investing activities: |
|||||||||
| Acquisition of property and equipment |
(383) |
(985) |
(696) |
(1,991) |
|||||
| Net cash used in investing activities |
(383) |
(985) |
(696) |
(1,991) |
|||||
| Cash flows from financing activities: |
|||||||||
| Repayment of capital lease obligations |
(360) |
(92) |
(661) |
(184) |
|||||
| Proceeds from sale-leaseback transactions |
- |
1,154 |
- |
1,154 |
|||||
| Repurchase of employee common stock for taxes withheld |
(17) |
- |
(234) |
(611) |
|||||
| Proceeds from vested restricted stock and exercise of stock options |
1,366 |
730 |
1,963 |
737 |
|||||
| Net cash provided by financing activities |
989 |
1,792 |
1,068 |
1,096 |
|||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash |
(1) |
402 |
359 |
649 |
|||||
| Increase (decrease) in cash, cash equivalents and restricted cash |
(61) |
3,720 |
(560) |
(714) |
|||||
| Cash, cash equivalents and restricted cash, at beginning of the period |
13,619 |
9,087 |
14,118 |
13,521 |
|||||
| Cash, cash equivalents and restricted cash, at end of the period |
$ 13,558 |
$ 12,807 |
$ 13,558 |
$ 12,807 |
|||||
| STAAR Surgical Company |
|||||||||||||
| Global Sales |
|||||||||||||
| (in 000's) |
|||||||||||||
| Unaudited |
|||||||||||||
| Three Months Ended |
Six Months Ended |
||||||||||||
| June 30, |
July 1, |
% Change |
June 30, |
July 1, |
% Change |
||||||||
| Sales by Region |
2017 |
2016 |
Fav (Unfav) |
2017 |
2016 |
Fav (Unfav) |
|||||||
| North America |
10.6% |
$ 2,336 |
12.0% |
$ 2,523 |
-7.4% |
10.9% |
$ 4,594 |
13.0% |
$ 5,224 |
-12.1% |
|||
| Europe, Middle East, Africa, Latin America |
31.2% |
6,839 |
32.2% |
6,751 |
1.3% |
32.1% |
13,592 |
31.8% |
12,779 |
6.4% |
|||
| Asia Pacific |
58.2% |
12,761 |
55.8% |
11,700 |
9.1% |
57.0% |
24,100 |
55.3% |
22,240 |
8.4% |
|||
| Total Sales |
100.0% |
$ 21,936 |
100.0% |
$ 20,974 |
4.6% |
100.0% |
$ 42,286 |
100.1% |
$ 40,243 |
5.1% |
|||
| Product Sales |
|||||||||||||
| ICLs |
74.4% |
$ 16,317 |
73.5% |
$ 15,408 |
5.9% |
74.7% |
$ 31,588 |
71.0% |
$ 28,588 |
10.5% |
|||
| IOLs |
20.0% |
4,377 |
24.2% |
5,068 |
-13.6% |
21.2% |
8,983 |
25.2% |
10,134 |
-11.4% |
|||
| Other |
5.7% |
1,242 |
2.4% |
498 |
149.4% |
4.1% |
1,715 |
3.8% |
1,521 |
12.8% |
|||
| Total Sales |
100.1% |
$ 21,936 |
100.1% |
$ 20,974 |
4.6% |
100.0% |
$ 42,286 |
100.0% |
$ 40,243 |
5.1% |
|||
| STAAR Surgical Company |
||||||
| Reconciliation of Non-GAAP Financial Measure |
||||||
| (in 000's) |
||||||
| Unaudited |
Three Months Ended |
Six Months Ended |
||||
| June 30, |
July 1, |
June 30, |
July 1, |
|||
| 2017 |
2016 |
2017 |
2016 |
|||
| Net loss - (as reported) |
$ (971) |
$(2,143) |
$ (3,174) |
$(10,184) |
||
| Less: |
||||||
| Foreign currency impact |
(380) |
416 |
(294) |
(42) |
||
| Stock-based compensation expense |
868 |
300 |
1,378 |
7,758 |
||
| Quality remediation expense |
43 |
491 |
210 |
1,000 |
||
| Net income (loss) - (adjusted) |
$ (440) |
$ (936) |
$ (1,880) |
$ (1,468) |
||
| Net income (loss) per share, basic - (as reported) |
$ (0.02) |
$ (0.05) |
$ (0.08) |
$ (0.25) |
||
| Foreign currency impact |
(0.01) |
0.01 |
(0.01) |
(0.00) |
||
| Stock-based compensation expense |
$ 0.02 |
0.01 |
0.03 |
0.19 |
||
| Quality remediation expense |
0.00 |
0.01 |
0.01 |
0.02 |
||
| Net income (loss) per share, basic - (adjusted) |
$ (0.01) |
$ (0.02) |
$ (0.05) |
$ (0.04) |
||
| Net income (loss) per share, diluted - (as reported) |
$ (0.02) |
$ (0.05) |
$ (0.08) |
$ (0.25) |
||
| Foreign currency impact |
(0.01) |
0.01 |
(0.01) |
(0.00) |
||
| Stock-based compensation expense |
0.02 |
0.01 |
0.03 |
0.19 |
||
| Quality remediation expense |
0.00 |
0.01 |
0.01 |
0.02 |
||
| Net income (loss) per share, diluted - (adjusted) |
$ (0.01) |
$ (0.02) |
$ (0.05) |
$ (0.04) |
||
| Weighted average shares outstanding - Basic |
40,933 |
40,210 |
40,841 |
40,097 |
||
| Weighted average shares outstanding - Diluted |
40,933 |
40,210 |
40,841 |
40,097 |
||
| Note: Net income (loss) per share (adjusted), basic and diluted, may not add due to rounding |
||||||
SOURCE STAAR Surgical Company
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article